21
https://pubmed.ncbi.nlm.nih.gov/38114289
Ocrelizumab, a multiple sclerosis treatment, can cause variable intestinal injury resembling inflammatory bowel disease and, rarely, acute hepatitis in the liver.
“Ocrelizumab for Multiple Sclerosis May Cause Intestinal Injury and Hepatitis”
